VACCINES MARKET ANALYSIS
The Global Vaccines Market is estimated to be valued at USD 77.12 Billion in 2024 and is expected to reach USD 116.10 Billion by 2031, exhibiting a compound annual growth rate (CAGR) of 6% from 2024 to 2031.
Discover market dynamics shaping the industry: Request sample copy
The global vaccines market is expected to witness a positive trend over the forecast period. Increased immunization programs by various governments and private organizations to curb the prevalence of diseases like influenza, measles, and etc. is driving the market growth. Furthermore, rising investments in research and development of novel vaccines for diseases without available preventions such as HIV/AIDS, and Ebola will provide new opportunities in the coming years. Introduction of technologically advanced vaccines and growing adult immunization are expected to augment the demand for vaccines between 2024 to 2031.
Growing awareness about immunization programs
With the advancements in medical research and technology over the past few decades, immunization has become one of the most effective interventions to protect public health. Several factors have led to higher awareness about vaccination in recent times globally. Health organizations like WHO and UNICEF have been carrying out extensive immunization drives and education campaigns globally, with a focus on developing nations. They have effectively educated the communities about vaccine-preventable diseases and how immunization can help eradicate them. As a result of these initiatives, people now understand better how immunization not only protects individuals but also contributes to herd immunity. The message that vaccinating children is every parent's responsibility has resonated strongly.
With growing digital penetration, access to health information is much wider than before. People extensively research online regarding recommended vaccination schedules and types of vaccines. They stay updated on disease outbreaks through news and social media. This has made them more cognizant of immunization as a key preventive healthcare measure. Also, as literacy levels improve across geographies, so does the health-seeking behaviour of societies. They recognize vaccination as the optimal way to shield against common but life-threatening illnesses. As more families witness the direct benefits of immunization first-hand among friends and relatives, its value becomes apparent. With no or minimal cases of diseases like polio, pertussis, and measles in communities following high immunization rates, vaccination gains trust as an effective public health intervention. Testimonials from those immunized spread the positive message furthers. The overall advancement in societal development has enhanced the perception and trust in modern medicine, including vaccines.
Get actionable strategies to beat competition: Request sample copy
Increasing investments by pharmaceutical companies for vaccine development
Pharmaceutical companies have recognized lucrative opportunities in the vaccines market, considering its steady rise driven by the above factors as well as others. This has motivated them to increase investment in vaccine R&D, as well as expansion activities to capitalize on the market’s potential. Vaccine production requires sophisticated technology and facilities due to the delicate nature of live attenuated and subunit vaccine components. It also necessitates extensive clinical trials to ensure efficacy and safety. Meeting these challenges demands heavy investment, which companies are willing to undertake seeing the vaccines business as a long-term proposition. They have been channelling greater budgets into new vaccine R&D focusing on both pediatric as well as adult diseases. This has already resulted in vaccines for HPV, Hepatitis B, pneumonia, etc. to enter the market.
Besides R&D spending, companies are expanding manufacturing plants and enhancing their production capacities. Many have set up or are setting up new facilities especially in high-growth vaccine markets like Asia and Africa. This is to reduce transportation costs as well as address local regulations. Companies are also making strategic acquisitions that boost their vaccine portfolios and market reach as well. For instance, Merck’s acquisition of Themis and GSK’s acquisition of Novartis Vaccines business. Furthermore, innovative financing and partnership models have come up, with GAVI acting as a major advocacy and funding agency. This has bolstered pharmaceuticals companies’ confidence in their investments, as viable business models and market readiness get demonstrated. Strong economic incentives encourage ongoing contributions to the vaccine portfolio, thereby strengthening public health protection. Thus, increased investments by major pharmaceutical companies have accelerated vaccine supply and development of novel vaccines.
Key Takeaways from Analyst:
The global vaccines market is expected to witness steady growth in the coming years. Rising prevalence of infectious diseases globally will drive demand for newer vaccines. Furthermore, growing population susceptibility towards various viruses owing to changing demographics and lifestyle patterns will provide a strong impetus to market players. Effective immunization programs by governments and private organizations aimed at eradicating deadly diseases will further aid the market expansion. However, stringent regulations involving vaccine approval and high costs associated with R&D may negatively impact revenue generation in the short-term.
Among various disease segments, the pediatric vaccines category will continue dominating the market landscape due to widespread distribution and availability of products targeting diseases mainly affecting children. On the other hand, the meningococcal vaccine segment is likely to experience fastest gains and emerge as the most lucrative segment towards the latter half of the forecast period.
Geographically, North America will retain its top position in the global vaccines industry supported by continuous funding for vaccine innovation and a favorable regulatory environment. Asia Pacific is anticipated to witness lucrative prospects and outpace other regions during the next few years. This can be attributed to improving healthcare infrastructure, rising disposable incomes, and expanding population base within the region. However, availability issues, cost constraints, and limited awareness in emerging nations might impede the regional vaccines market to an extent.
Market Challenges: Stringent Regulatory Environment
The global vaccines market continues to face significant challenges from the stringent regulatory environment governing product development, manufacturing, and marketing authorization. Obtaining regulatory approvals for vaccines from organizations like the FDA and EMA is a long-drawn and complex process involving extensive clinical trials to demonstrate safety, efficacy, and quality. Even minor changes to existing vaccines may require additional trials and approvals, creating delays. Furthermore, regulations around production facilities and quality systems adherence during manufacturing are extensive. Maintaining full compliance increases operational costs significantly for companies. Finally, regulatory laws also determine pricing and market access pathways for new vaccines. The extensive and evolving regulatory frameworks continue to impact the productivity and performance of players in the global vaccines market.
Market Opportunities: Increase in Immunization Coverage
The global vaccines market has a huge opportunity arising from the rising focus on increasing immunization coverage across regions. Initiatives by governments and non-profit organizations to boost immunization rates for diseases like COVID-19, influenza, HPV, and pneumonia have raised population immunity levels. According to the WHO, vaccination programs prevented at least 10 million deaths globally over the last decade. Continued efforts towards ensuring vaccination access in developing and underdeveloped markets can further push demand. Market leaders are increasingly prioritizing developmental work and partnerships to cater to such emerging markets. With the rising understanding of immunization importance, greater financing and stability in vaccination programs are expected. This will likely drive higher revenues for vaccines manufacturing companies in the coming years.
Discover high revenue pocket segments and roadmap to it: Request sample copy
By Type- Advancements in Medical Technology Drive Growth in Monovalent Vaccines
In terms of Type, Monovalent Vaccines is estimated to account for the highest market share, contributing 59.1% in 2024, driven by ongoing advancements in medical technology. Developments in genomics and immunology have allowed scientists to create highly targeted monovalent vaccines that provide protection against specific deadly diseases. This focus on single pathogens makes monovalent vaccines very effective at preventing illness and compatible with disease eradication goals. They also have high specificity which enables protection without interfering reactions from additional vaccine components. Rapid developments in DNA sequencing and genetic engineering now facilitate the design of novel monovalent vaccines in short periods of time at reduced costs. This allows public health organizations to respond quickly to emerging outbreaks and roll out new vaccines targeting seasonal influenza strains on annual cycles. The precision and flexibility of monovalent vaccines appeals to regulatory bodies and enhances uptake.
By Technology- Technological Synergies Foster Growth in Conjugate Vaccines
In terms of Technology, Conjugate Vaccines is projected to account for the highest market share, contributing 42% in 2024 owing to technological synergies across fields. Conjugate vaccines combine antigens from bacteria or toxins with immune stimulants to amplify the body's immune response. Recent progress in materials science and surface chemistry advance the way antigens couple to carrier proteins, enhancing stability and immunogenicity. Biotechnology innovations facilitate mass production of customized carrier-antigen molecules through bacterial fermentation. Insights from immunology also optimize adjuvant selection and dosing to maximize memory cell induction. These technological synergies empower conjugate vaccines to provoke stronger, longer-lasting protection against complex diseases than earlier alternatives. Their sophisticated design resonates with public health goals of expanding immunization schedules with fewer doses.
By Disease Indication- Patient Convenience Drives Preference for Oral Tablet/Capsule Formulations
Based on the segmentation by disease indication, the dominant segment in the global vaccine market is pneumococcal disease which is projected to contribute highest share of 32% in 2024. The Pneumococcal Disease segment is the largest and most dominant in the global vaccine market, accounting for a significant market share. This dominance is primarily driven by the high prevalence of pneumococcal infections, which can lead to severe and potentially life-threatening conditions such as pneumonia, meningitis, and sepsis, particularly among the elderly and young children. The growing awareness of the importance of pneumococcal vaccination, coupled with the availability of highly effective and safe pneumococcal vaccines, has led to increased adoption and demand for these vaccines globally. Additionally, government initiatives and programs aimed at improving vaccination coverage, especially in developing countries, have further contributed to the dominance of the pneumococcal disease segment. Other disease indications segment, such as Influenza, Combination Vaccines, and Herpes Zoster, also hold sizable market shares and are expected to witness steady growth in the coming years. However, the pneumococcal disease segment is likely to maintain its dominant position due to the continuous efforts to expand vaccination coverage and the ongoing development of more advanced pneumococcal vaccine formulations.
To learn more about this report, Request sample copy
North America has established itself as the dominant regional market for vaccines globally with an estimated share of 40.3% in 2024. The presence of large pharmaceutical companies with strong research and development capabilities in countries like the U.S. has enabled the region to continually introduce innovative vaccines. In addition, favorable government policies that provide funding for vaccine research and development as well as high healthcare expenditure have facilitated market growth. Countries in the region have a well-established cold chain logistics network for efficient storage and distribution of temperature sensitive vaccines. Rising administration of vaccines due to growing public health awareness among consumers has further increased demand.
The Asia Pacific region has emerged as the fastest growing regional market for vaccines globally in recent years. Rapid economic development and growth of healthcare infrastructure in countries like China and India have significantly boosted the market. Rising disposable incomes have also increased affordability of vaccines for a larger consumer base. Governments of various countries have launched extensive national immunization programs to increase vaccine coverage rates against diseases. This has presented lucrative business opportunities for vaccines manufacturers. Additionally, the large population size of the region requiring vaccination makes it an attractive market for future investments.
As new vaccines are continuously being developed to prevent additional diseases, technological advancements in vaccine production are crucial to improve affordability. While North America currently dominates due to a favorable environment for research, the Asia Pacific region exhibits high potential for vaccines companies to expand their consumer base and tap into future growth opportunities through strategic investments and collaborative partnerships. Overall, both regions play a pivotal role in the continued progress of the global vaccines industry.
Vaccines Market Report Coverage
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 77.12 Bn |
| Historical Data for: | 2019 To 2023 | Forecast Period: | 2024 To 2031 |
| Forecast Period 2024 to 2031 CAGR: | 6% | 2031 Value Projection: | US$ 116.10 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
GlaxoSmithKline plc (GSK), Merck & Co., Inc., Pfizer Inc., Sanofi, Moderna, Inc., AstraZeneca, Johnson & Johnson, Novavax, Inc., CSL Limited, Emergent BioSolutions Inc., Bharat Biotech, Serum Institute of India, BioNTech SE, Takeda Pharmaceutical Company, Sinovac Biotech Ltd., Sinopharm (China National Pharmaceutical Group), Vaxart, Inc., Inovio Pharmaceuticals, Inc., Valneva SE, Vaccitech plc |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
*Definition: The global vaccines market comprises companies engaged in the research, development, manufacturing, and marketing of vaccines for both human and veterinary use. Key categories of vaccines in this market include preventive vaccines such as those for measles, mumps, and rubella (MMR), polio, influenza, pneumococcal disease, and meningococcal disease. The market's growth is fueled by increased government funding for immunization programs, heightened awareness of vaccine-preventable diseases, and advancements in the biotechnology and pharmaceutical sectors. Leading market players are heavily invested in R&D to create newer and more effective vaccines.
Share
About Author
Nikhilesh Ravindra Patel is a Senior Consultant with over 8 years of consulting experience. He excels in market estimations, market insights, and identifying trends and opportunities. His deep understanding of the market dynamics and ability to pinpoint growth areas make him an invaluable asset in guiding clients toward informed business decisions. He plays a instrumental role in providing market intelligence, business intelligence, and competitive intelligence services through the reports.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Credibility and Certifications
860519526
9001:2015
27001:2022
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowSelect a License Type
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 